Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC33 vs placebo in previously treated advanced hepatocellular carcinoma
jRCT2080221779Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing GC33 1600 mg IV Q2W with Placebo IV Q2W (2 arms).
02
Drugs
codrituzumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221779.